MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
2. Triple Helix _ Funding
*Funding: Architects_Small Business
Intermediaries: Triple Helix, Technology Exchanges, Open Innovation & Illiquid Secondary Market Makers
*Architects: Triple Helix, IP and Technology Exchanges, Open Innovation & Illiquid Secondary Market Makers
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY)*
Organization & Developments: Alnylam
*Organization: Alnylam
Parents
Organization & Developments: Alnylam
Children
*ATTR amyloidosis can lead to significant morbidity, disability, and mortality.
*Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development of microRNA
*RNA interference-based pharmaceuticals
*RNAi creates the opportunity to silence the production of disease-causing proteins and therefore, represents a whole new approac
*This disease is a progressive, life-threatening disease caused by misfolded transthyretin ("TTR") proteins that accumulate as amyloid fibrils in multiple organs, but primarily in the peripheral nerves and heart.
2016: Its most advance trials are in Phase III targeting hereditary ATTR amyloidosis.
Jumps
*Developments: Alnylam